Merz North America has signed an agreement with Brickell Biotech, granting Merz an exclusive North American license, with certain additional international rights, to develop and commercialize a novel retinoid compound for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis. Under the terms of the agreement, Merz North America will assume the full cost and responsibility for future development and commercialization, initially for North America.
In preclinical studies performed by Brickell, the patent-protected retinoid therapy displayed activity which differentiated it from the leading topical retinoids currently available on the market.
“As Merz North America continues to expand its presence in the U.S. medical dermatology space, we are excited to continue the clinical development of this new chemical entity (NCE) via our own in-house research and development expertise,” said Bill Humphries, president & CEO of Merz North America. “By pursuing a targeted, long-term growth strategy, we will continue to provide physicians and their patients with new treatment options that set the standard for quality and innovation in medical and aesthetic dermatology.”
